Our data provide the blueprint for a universal anti‐COVID‐19 agent with the potential to treat or even prevent infections against all current and potentially also future SARS‐CoV‐2 variants, as well as novel emerging coronaviruses using ACE2 as cell entry receptor. This evidence concerns the gene ACE2 and infection.